Department of Pathology and Pathophysiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Jinan Microecological Biomedicine Shandong Laboratory, Jinan 250117, China.
Biomolecules. 2024 Jul 4;14(7):794. doi: 10.3390/biom14070794.
Many drug and therapeutic modalities have emerged over the past few years. However, successful commercialization is dependent on their safety and efficacy evaluations. Several preclinical models are available for drug-screening and safety evaluations, including cellular- and molecular-level models, tissue and organoid models, and animal models. Organoids are three-dimensional cell cultures derived from primary tissues or stem cells that are structurally and functionally similar to the original organs and can self-renew, and they are used to establish various disease models. Human hepatobiliary organoids have been used to study the pathogenesis of diseases, such as hepatitis, liver fibrosis, hepatocellular carcinoma, primary sclerosing cholangitis and biliary tract cancer, as they retain the physiological and histological characteristics of the liver and bile ducts. Here, we review recent research progress in validating drug toxicity, drug screening and personalized therapy for hepatobiliary-related diseases using human hepatobiliary organoid models, discuss the challenges encountered in current research and evaluate the possible solutions.
近年来出现了许多药物和治疗方法。然而,它们的成功商业化取决于其安全性和疗效评估。有几种临床前模型可用于药物筛选和安全性评估,包括细胞和分子水平的模型、组织和类器官模型以及动物模型。类器官是从原组织或干细胞中提取的三维细胞培养物,在结构和功能上与原始器官相似,能够自我更新,用于建立各种疾病模型。人肝胆管类器官已用于研究肝炎、肝纤维化、肝癌、原发性硬化性胆管炎和胆道癌等疾病的发病机制,因为它们保留了肝脏和胆管的生理和组织学特征。在这里,我们综述了使用人肝胆管类器官模型验证药物毒性、药物筛选和肝胆相关疾病的个体化治疗的最新研究进展,讨论了当前研究中遇到的挑战,并评估了可能的解决方案。